The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study.

@article{Baccarani2007TheEO,
  title={The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study.},
  author={Michele Baccarani and Daniela Cilloni and Michela Rondoni and Emanuela Ottaviani and Francesca Messa and Serena Merante and Mario Tiribelli and Francesco Buccisano and Nicoletta Testoni and Enrico Marco Gottardi and Antonio de Vivo and Emilia Giugliano and Ilaria Iacobucci and Stefania Paolini and Simona Soverini and Gianantonio Rosti and Francesca Rancati and Cinzia Astolfi and Marco Picardi Fabrizio Pane and Giuseppe Saglio and G. Failla O Martinelli},
  journal={Haematologica},
  year={2007},
  volume={92 9},
  pages={
          1173-9
        }
}
BACKGROUND AND OBJECTIVES The hypereosinophilic syndrome (HES) may be associated with the fusion of the platelet derived growth factor receptor a (PDGFRalpha) gene with the FIP1L1 gene in chromosome 4 coding for a constitutively activated PDGFRalpha tyrosine kinase. These cases with FIP1L1-PDGFRalpha rearrangement have been reported to be very sensitive to the tyrosine kinase inhibitor imatinib mesylate. DESIGN AND METHODS A prospective multicenter study of idiopathic or primary HES was… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 73 CITATIONS, ESTIMATED Infinity% COVERAGE

73 Citations

0510'09'12'15'18
Citations per Year
Semantic Scholar estimates that this publication has 73 citations based on the available data.

See our FAQ for additional information.

References

Publications referenced by this paper.
SHOWING 1-10 OF 45 REFERENCES

Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the haematologica/the hematology journal

  • AD Klion, J Robyn, C Akin, P Noel, M Brown, M Law
  • Blood
  • 2007
3 Excerpts

FIP 1 L 1 - PDGFRalpha positive hypereosinophilic syndrome ( HES ) . The response to Imatinib ( IM ) is durable . A report of 21 patients with a follow - up of 12 to 57 months

  • M David, NC Cross, S Burgstaller, A Chase, C Curtis, R Dang
  • Blood
  • 2006

Similar Papers

Loading similar papers…